In the future, you could be your very own fountain of youth – or at least your own skin repair reservoir. In a proof-of-concept study, researchers from North Carolina State University have shown that exosomes harvested from human skin cells are more effective at repairing sun-damaged skin cells in mice than popular retinol or stem cell-based treatments currently in use. Additionally, the nanometer-sized exosomes can be delivered to the target cells via needle-free injections.
Exosomes are tiny sacs (30 – 150 nanometers across) that are excreted and taken up by cells. They can transfer DNA, RNA or proteins from cell to cell, affecting the function of the recipient cell. In the regenerative medicine field, exosomes are being tested as carriers of stem cell-based treatments for diseases ranging from heart disease to respiratory disorders.
“Think of an exosome as an envelope with instructions inside – like one cell mailing a letter to another cell and telling it what to do,” says Ke Cheng, professor of molecular biomedical sciences at NC State, professor in the NC State/UNC-Chapel Hill Joint Department of Biomedical Engineering and corresponding author of a paper describing the work. “In this case, the envelope contains microRNA, non-coding RNA that instructs the recipient cell to produce more collagen.”
To test whether exosomes could be effective for skin repair, Cheng and his team first grew and harvested exosomes from skin cells. They used commercially available human dermal fibroblast cells, expanding them in a suspension culture that allowed the cells to adhere to one another, forming spheroids. The spheroids then excreted exosomes into the media.
“These 3D structures generate more procollagen – more potent exosomes – than you get with 2D cell expansion,” says Cheng.
In a photoaged, nude mouse model, Cheng tested the 3D spheroid-grown exosomes against three other treatments: retinoid cream; 2D-grown exosomes; and bone marrow derived mesenchymal stem cells (MSCs) exosomes, a popular stem cell-based anti-aging treatment currently in use. The team compared improvements in skin thickness and collagen production after treatment. They found that skin thickness in 3D exosome treated mice was 20% better than in the untreated and 5% better than in the MSC-treated mouse. Additionally, they found 30% more collagen production in skin treated with the 3D exosomes than in the MSC treated skin, which was the second most effective treatment.
“I think this study shows the potential for 3D exosomes to be used in anti-aging skin treatments,” says Cheng. “There are two major benefits to exosome treatments over conventional treatments: one, you can use donor skin cells from anyone to grow and harvest these exosomes – they aren’t cells, so you don’t run the risk of rejection. And two, the treatment can be administered without needles – exosomes are small enough to be able to penetrate the skin via pressure, or jet injection methods.
“Our hope is that eventually people may be able to ‘bank’ skin samples and come back to them, or use donor exosome treatments that they can administer themselves. We believe that this work is an important step toward potentiating future human clinical trials in the prevention and treatment of cutaneous aging.”
Learn more: Suntanner, Heal Thyself: Exosome Therapy May Enable Better Repair of Sun, Age-Damaged Skin
The Latest on: Exosome treatments
[google_news title=”” keyword=”exosome treatments” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Exosome treatments
- ZTX Becomes Payment Option for Real World Medical Services In Japanon April 30, 2024 at 7:18 am
ZTX, the Web3 social metaverse platform, is partnering with Frontier, a leading Japanese operator and distributor of regenerative medicine, to offer its native ZTX token as a payment method for ...
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technologyon April 30, 2024 at 5:30 am
Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — ...
- SickScience Tackles Hair Growth With Second Producton April 28, 2024 at 9:01 pm
Just seven weeks after launching, SickScience is already tackling a new category — hair. The biotech brand has harnessed its hero ingredient, NX35 Growth Technology, in addition to garlic and ...
- Coya Therapeutics CEO Discusses Company's Treatment Pipelineon April 26, 2024 at 12:16 pm
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a look at the organization's pipeline.
- EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trialon April 25, 2024 at 2:01 am
"EXO Biologics hopes to gain conditional marketing from Phase I/II BPD trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. Top-notch biotech stock ...
- Blossom Hotel Houston opens restaurant backed by Michelin-starred chefson April 23, 2024 at 11:07 am
Blossom Hotel Houston near the Texas Medical Center has opened its first restaurant: a high-end Asian concept run by two Michelin-starred chefs.
- Stem Cell Magic: Scientists Unveil New Superhero for Healing Diabetes Woundson April 23, 2024 at 10:13 am
Researchers unveiled a novel therapy for diabetic wound healing. The new research highlights the use of exosomal miR-4645-5p from hypoxic bone marrow mesenchymal stem cells (BMSCs) to significantly ...
- Are exosomes better than stem cells in battling aging?on April 22, 2024 at 10:00 pm
“If the body is not functioning at its maximum performance despite a balanced diet and adequate supplementation, these mesenchymal stem cell (MSC)-derived exosomes can endow the body with restorative ...
- Duke mechanical engineers develop more efficient diagnostic platform for cancer, other diseaseson April 22, 2024 at 4:48 pm
A team of mechanical engineers has created a new diagnostic platform that can be used to detect various cancers and other serious medical conditions with greater efficiency.
- Study finds promising biomarker for cellular rejection after organ transplanton April 18, 2024 at 7:19 am
Today, patients who receive an organ transplant need repeated surgical biopsies to test for acute cellular rejection (ACR) throughout their lifetimes. But a blood test for ACR could be on the horizon ...
via Bing News